Cargando…

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

INTRODUCTION: Anti-PD-1 therapies, pembrolizumab and nivolumab, are currently the standard of care for treatment of patients with metastatic melanoma. Treatment is usually continued until toxicity or disease progression. Though these therapies are well tolerated, some patients discontinue them due t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swami, Umang, Monga, Varun, Bossler, Aaron D., Zakharia, Yousef, Milhem, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683789/ https://www.ncbi.nlm.nih.gov/pubmed/31428149 http://dx.doi.org/10.1155/2019/1856594

Ejemplares similares

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
por: Swami, Umang, et al.
Publicado: (2020)

Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study
por: Zakharia, Yousef, et al.
Publicado: (2017)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
por: Swami, Umang, et al.
Publicado: (2019)

Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
por: Greco, Austin, et al.
Publicado: (2019)

Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021)

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas
por: Monga, Varun, et al.
Publicado: (2018)

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy
por: Rieth, John M., et al.
Publicado: (2021)

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
por: Pokorny, Rebecca, et al.
Publicado: (2021)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

The Genetics of Early-Stage Melanoma in a Veteran Population
por: Cheung, Kevin, et al.
Publicado: (2022)

Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report
por: Umihira, Shuntaro, et al.
Publicado: (2022)

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
por: Ellingsen, Espen B., et al.
Publicado: (2023)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
por: Ribas, Antoni, et al.
Publicado: (2021)

Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
por: Rytlewski, Jeff, et al.
Publicado: (2021)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

Non-Conventional Treatments for Conventional Chondrosarcoma
por: Monga, Varun, et al.
Publicado: (2020)

Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
por: Alexander, Swetha, et al.
Publicado: (2021)

Newer Antiepileptic Drugs Discontinuation due to Adverse Effects: An Observational Study
por: Golpayegani, Mehdi, et al.
Publicado: (2019)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
por: Tachihara, Motoko, et al.
Publicado: (2018)

Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice
por: van Zeijl, Michiel C. T., et al.
Publicado: (2021)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
por: Nikolaou, Vasiliki, et al.
Publicado: (2023)

Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases
por: Phadke, Sneha D., et al.
Publicado: (2016)

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
por: Wang, Jie, et al.
Publicado: (2019)

Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy
por: Wu, Xia, et al.
Publicado: (2021)

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
por: Galvani, Elena, et al.
Publicado: (2020)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
por: Rytlewski, Jeff, et al.
Publicado: (2022)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

Discontinuation of Levetiracetam and Valproic Acid Due to Adverse Effects in Early Post-traumatic Seizure Prophylaxis
por: Pathak, Sami M, et al.
Publicado: (2023)

Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma
por: Mulder, Evalyn E.A.P., et al.
Publicado: (2022)

A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
por: Leiserson, Mark D. M., et al.
Publicado: (2018)

Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy
por: Yeung, Howa, et al.
Publicado: (2023)

Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44
por: Wessels, Deborah, et al.
Publicado: (2017)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in Mycobacterium avium Complex Lung Disease
por: Kwon, Yong Shik, et al.
Publicado: (2020)

Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease
por: Chen, George L., et al.
Publicado: (2022)

Durable discontinuation of systemic therapy for chronic graft-versus-host disease: myth or reality?
por: Pavletic, Steven Z., et al.
Publicado: (2022)

Statin discontinuation: counterbalancing the benefits with the potential risks
por: Paraskevas, Kosmas I., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jvknrfumqmcn2f5t19h0vbqkva